CClinicalTrials.gg
RecruitingNCT07088198Updated Jul 28, 2025

Joshi's Step With Buccal Mucosal Graft Urethroplasty in Nearly Obliterated Bulbar Urethral Stricture

An interventional study of Joshi's step in Joshi's Step, Buccal Mucosal Graft and Urethroplasty, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled May 2024, registered Jul 2025).
  • Started May 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study aims to evaluate the functional and surgical outcome of Joshi's step with buccal graft urethroplasty for the management of nearly obliterated bulbar urethral stricture.

Read the detailed description

Urethroplasty is a rapidly evolving art that continually improves and reinvents itself. After a century of silence, during which the anastomotic repair was the only solution for approaching the strictured urethra, the 1990s can be considered the Renaissance period for reconstructive urology.

In 2022, Joshi and Kulkarni introduced a new step to the augmented urethroplasty, particularly in patients with extremely narrow strictures where a single augmentation was insufficient. They avoid any resection of the residual native urethral plate, marking the narrowest portion. Then, the edges of the mucosa are reapproximated with interrupted suturing in a proper non-resecting approach.

02

Conditions studied

  • Joshi's Step
  • Buccal Mucosal Graft
  • Urethroplasty
  • Obliterated Bulbar Urethral Stricture
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with primary bulbar urethral stricture.
  • Patients with non-traumatic bulbar urethral stricture.
  • Patients with nearly obliterated bulbar urethral stricture, with the narrowest portion of the stricture is less than 1.5 cm in length.

Exclusion criteria

Exclusion Criteria:

  • Patients with traumatic bulbar urethral stricture.
  • Patients with redo bulbar urethral stricture.
  • Patients with obliterated bulbar urethral stricture.
  • Patients with nearly obliterated long bulbar urethral stricture.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Study group

    Patients will undergo dorsal onlay buccal mucosal graft urethroplasty with Joshi's step

    Procedure: Joshi's step

Interventions

  • ProcedureJoshi's step

    Patients will undergo dorsal onlay buccal mucosal graft urethroplasty with Joshi's step

06

What researchers measure

Primary outcomes

  1. Success rate

    Incidence of success rate will be recorded.

    Time frame: 6 months postoperatively

Secondary outcomes

  1. Urine flow rate

    Urine flow rate will be recorded.

    Time frame: 6 months postoperatively

  2. The urethral lumen

    The urethral lumen by ascending urethrogram will be recorded.

    Time frame: 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07088198
Lead sponsor
Tanta University
Responsible party
Mohamed Ibrahim Ahmed Elmaadawy (Lecturer of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt, Tanta University) — Principal investigator
First posted
Jul 28, 2025
Start date
May 1, 2024
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Jul 28, 2025

Study contacts

Mohamed I Elmaadawy, MD
Contact
Mohamed.elmaadawy@med.tanta.edu.eg
00201060245430

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion